Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026

Swedish biotech Cereno Scientific has announced a collaboration with PHA Europe & Global, aimed at integrating the patient perspective more systematically into clinical trial design and execution. Cereno is developing two experimental medications that could expand choices in this space: CS1 for pulmonary arterial hypertension (PAH) and CS014 for pulmonary hypertension associated with lung disease (PH-ILD). The […]

Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026 Read Post »

PHA Europe held its Annual Pulmonary Hypertension European Conference (APHEC) on November 8-12, 2023, featuring representatives of the scientific, patient, and health care communities

The European Association for Pulmonary Hypertension, PHA Europe, held its Annual European Pulmonary Hypertension Conference (APHEC) in Barcelona from 8-12 November 2023 in Castelledefels, Barcelona (Spain). The conference featured presentations by distinguished members of the scientific community (Prof. Adam Torbicki, Poland; Prof. Jean-Luc Vachiéry, Belgium; Prof Joanna Pepke-Zabka, UK; Prof. Jimmy Ford, USA; Prof. Dr.

PHA Europe held its Annual Pulmonary Hypertension European Conference (APHEC) on November 8-12, 2023, featuring representatives of the scientific, patient, and health care communities Read Post »

TRANSLATE »
Scroll to Top